Innoviva, Inc Stock News

With another 2020 stock market crash right around the corner, there are two cheap FTSE 100 shares I'd buy right now, says Tom Rodgers.

Sanofi and GSK expect to begin Phase 1/2 trials of a COVID-19 vaccine in September, with Phase 3 clinical trials beginning at the end of 2020.

En pleine course aux vaccins contre le Covid-19, les deux colosses pharmaceutiques ont décroché deux contrats annoncés ce vendredi. Ils vont recevoir jusqu'à 2,1 milliards de dollars des Etats-Un

European drugmakers Sanofi and GlaxoSmithKline said Friday they will receive funding from the U.S. government to aid in the development and manufacture of their COVID-19 vaccine.

The deal, announced by the U.S. Department of Health and Human Services and Department of Defense, works out at a cost of around $42 per person inoculated.

Stocks ended July on a high note as Big Tech fueled gains for the major averages.

The coronavirus has infected more than 17.3 million people around the world as of Friday, killing at least 673,822 people.

U.S. listed shares of Sanofi undefined gained 0.8% in premarket trading on Friday after it said the U.S. government will pay up to $2.1 billion for the...

The deal contracts Sanofi and GlaxoKlineSmith to provide the US with enough doses of their vaccine to inoculate 50 million Americans at a price of about $42 per person - if it is effective.

Operation Warp Speed will provide up to $2.1 billion to Sanofi and GlaxoSmithKline to fund development and manufacturing of the companies' Covid-19 vaccine.

The agreement with Sanofi and GlaxoSmithKelin is the government's second in less than two weeks for 100 million doses of vaccine.

The deal appears to price the vaccine at less than $10.50 a dose.